Reversal of established responses to endothelin‐1 in vivo and in vitro by the endothelin receptor antagonists, BQ‐123 and PD 145065
Open Access
- 1 May 1994
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 112 (1) , 207-213
Abstract
Endothelin‐1 binds almost irreversibly to its receptors and causes prolonged vasoconstrictions. Here we have studied the reversal of established responses to ET‐1 in vivo and in vitro by BQ‐123, an ETA receptor‐selective antagonist, and/or PD 145065, an ETA/ETB receptor non‐selective antagonist. In anaesthetized rats pretreated with hexamethonium, infusion of ET‐1 (10−11 mol kg−1 min−1) increased the mean arterial pressure (MAP) from 93 ± 1.5 mmHg to 137 ± 2.4 mmHg after 70 min (n = 29). While the ET‐1 infusion was continued an additional infusion of BQ‐123 caused a gradual dose‐dependent reduction in the pressor effect of ET‐1. For instance, after a 60 min infusion of BQ‐123 (10−8 mol kg−1 min−1) the MAP was decreased by 29.3 ± 4.3 mmHg (n = 4). PD 145065 was a much weaker antagonist of the established pressor effects of ET‐1. At 10−8 mol kg−1 min−1 it had no significant effect and even at 10−7 mol kg−1 min−1 the elevated blood pressure was only reduced by 11.8 ± 8.0 mmHg (n = 5) after 60 min. Co‐infusion of BQ‐123 and PD 145065 caused smaller reductions in the established response to ET‐1 than infusion of BQ‐123 alone. Sustained contractions of rat aortic rings induced by ET‐1 (3 × 10−9 m) and mediated by ETA receptors were slowly reversed by addition of BQ‐123 (10−5 m) or PD 145065 (10−5 m). For instance, after 40 min the elevated tone was reduced 85.8 ± 5.6% (n = 6) by PD 145065, and 77.1 ± 6.7% (n = 6) by BQ‐123. Thus, on the rat aortic rings in vitro both antagonists were equally effective against established responses to ET‐1. ET‐1 increased the perfusion pressure of the rat isolated perfused kidney by 138.1 ± 7.6 mmHg (n = 14). Subsequent co‐infusion of BQ‐123 or PD 145065 reversed this increase with PD 145065 being more active. For instance, PD 145065 (10−6 m) reversed the increase in perfusion pressure by 56.9 ± 8.8% (n = 5) and BQ‐123 (10−6 m) reversed it by 22.8 ± 8.0% (n = 5). This fits well with the vasoconstriction induced by ET‐1 in the rat kidney being mediated by ETA and ETB receptors. Thus, sustained vasoconstrictions to ET‐1 in vitro, mediated by either ETA or ETB receptors, may be reversed slowly by the subsequent application of receptor antagonists. Similarly, endothelin antagonists reverse the pressor effects of ET‐1 in vivo although co‐antagonism of ETA and ETB receptors or the co‐administration of an ETA receptor antagonist, BQ‐123, and a mixed antagonist, PD 145065 produces less reversal than the application of an ETA receptor‐selective antagonist. This may be because PD 145065 also reduces vasodilatations induced by ET‐1 in vivo, or could suggest that because of its peptide structure PD 145065 affects the elimination of ET‐1.Keywords
This publication has 29 references indexed in Scilit:
- In Vitro and In Vivo Studies with a Series of Hexapeptide Endothelin AntagonistsJournal of Cardiovascular Pharmacology, 1993
- Kinetic analyses demonstrate that the equilibrium assumption does not apply to [125I]endothelin-1 binding dataLife Sciences, 1992
- Pharmacologic Characterization of an EndothelinA (ETA) Receptor Antagonist in Conscious RatsJournal of Cardiovascular Pharmacology, 1992
- Venous smooth muscle contains vasoconstrictor ETB-like receptorsBiochemical and Biophysical Research Communications, 1992
- Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptorLife Sciences, 1992
- Presence of non‐selective type of endothelin receptor on vascular endothelium and its linkage to vasodilationFEBS Letters, 1991
- Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptorNature, 1990
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- The Fate of Radioiodinated Endothelin-1 and Endothelin-3 in the RatJournal of Cardiovascular Pharmacology, 1989
- Cellular mechanism of action by a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cellsBiochemical and Biophysical Research Communications, 1988